US-Iran Ceasefire Talks Underway: What You Need to Know 
UK Regulators Demand Social Media Platforms Strengthen Children's Age Verification 
Cyberattack on Stryker Triggers U.S. Government Warning Over Microsoft Intune Security 
Taiwan Arms Deal on Track Despite U.S.-China Summit Uncertainty 
Asian Stocks Gain Amid Iran Conflict Uncertainty 
Iran Demands Lebanon Be Part of Any Ceasefire Deal With Israel and the U.S. 
Iran-U.S. Negotiations: Tehran Reviews American Peace Proposal Amid Ongoing Gulf Conflict 
Trump's Overhaul of American History: Museums, Monuments, and Cultural Institutions 
Trump Seeks Quick End to U.S.-Iran Conflict Amid Ongoing Middle East Tensions 
U.S. Deploys Elite 82nd Airborne Troops to Middle East Amid Iran Tensions 
Trump Threatens ICE Airport Deployment Amid TSA Shutdown Crisis 
Gold Prices Fall for Tenth Straight Session Amid Iran Uncertainty and Rate Concerns 
Japan's Private Sector Growth Slows in March Amid Rising Costs and Middle East Uncertainty 
Bank of Japan Eyes April Rate Hike Despite Inflation Dip, ING Says 
FEMA Reinstates $1 Billion Disaster Prevention Grant Program After Court Order 
Trump Administration Opens Two New Investigations Into Harvard Over Discrimination and Antisemitism 
U.S. President Donald Trump announced sweeping new trade tariffs Thursday evening, including a 100% levy on imported pharmaceutical products, marking one of his most aggressive moves to date in reshaping America’s trade policy. The new tariffs, set to take effect October 1, will also include a 25% duty on heavy truck imports, 50% on kitchen and bathroom fittings, and 30% on upholstered furniture.
According to Trump, the pharmaceutical tariffs will apply to all branded or patented products, though companies actively building manufacturing plants in the United States will be exempt. He specified that firms must have already broken ground or begun construction on U.S. facilities to qualify. Trump framed the move as a matter of national security and a necessary step to reduce dependency on foreign drug imports.
The United States imported over $212 billion worth of pharmaceutical products in 2024, government data shows. Trump has long criticized this reliance, arguing that it threatens U.S. security and weakens domestic industries. Earlier this year, he demanded that 17 major drugmakers lower domestic drug prices while raising them abroad to balance profits. In August, Trump warned he could hike tariffs as high as 250%, signaling the seriousness of his push for reshoring production.
The tariff threats have already spurred huge investment pledges from global pharma companies. Roche committed to investing $50 billion, while Novartis announced $23 billion in U.S. facilities. American firms including Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Company (NYSE:LLY) are also ramping up domestic operations to hedge against the new trade policies.
These tariffs extend beyond pharmaceuticals, targeting industries like heavy trucks, fittings, and furniture—sectors Trump says need protection to revive U.S. manufacturing and safeguard jobs. While the full impact of these measures on trade partners remains unclear, they underscore the administration’s continued reliance on tariffs as a core tool in its economic agenda.
